A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation.
Publication
, Conference
Patnaik, A; Pelster, M; Hong, DS; Strickler, JH; Garrido-Laguna, I; Aguirre, A; Curran, D; Woo, T; Spira, AI
Published in: JOURNAL OF CLINICAL ONCOLOGY
2024
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Patnaik, A., Pelster, M., Hong, D. S., Strickler, J. H., Garrido-Laguna, I., Aguirre, A., … Spira, A. I. (2024). A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Patnaik, Amita, Meredith Pelster, David S. Hong, John H. Strickler, Ignacio Garrido-Laguna, Andrew Aguirre, Dominic Curran, Tina Woo, and Alexander I. Spira. “A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.
Patnaik A, Pelster M, Hong DS, Strickler JH, Garrido-Laguna I, Aguirre A, et al. A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.
Patnaik, Amita, et al. “A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.
Patnaik A, Pelster M, Hong DS, Strickler JH, Garrido-Laguna I, Aguirre A, Curran D, Woo T, Spira AI. A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation. JOURNAL OF CLINICAL ONCOLOGY. 2024.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences